BSX · 8-K · 20261007PR000064

Leadership Transition

BOSTON SCIENTIFIC CORP · 2026-10-07 · Importance 31 · Surprise 42

Boston Scientific appointed Joseph M. Fitzgerald executive vice president and chief operating officer, effective January 1, 2027, with responsibility for global operations, business units and regions. On the same date, the company will establish three reportable segments: Interventional Therapies, Rhythm Solutions and MedSurg. Management said the operating model is intended to accelerate decision-making and support strategic allocation of investments across the portfolio. Interventional Therapies will include the Penumbra business following the anticipated acquisition close, while regional and business leaders will report to Fitzgerald.

Key facts

• Boston Scientific Corporation announced the appointment of Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027. source
• Lance Bates, executive vice president and president, Interventional Therapies, will lead the global Interventional Therapies segment. source
• Nick Spadea-Anello, executive vice president and president, Atrial Fibrillation Solutions, will lead the global Rhythm Solutions segment. source
• Stephen Morse, senior vice president and president, Asia Pacific, will serve as executive vice president and president, MedSurg and Asia Pacific. source
• In his role as COO, Fitzgerald will oversee the company’s global operations, business units and regions. source
• Each of the segment presidents (Lance Bates, Nick Spadea-Anello and Stephen Morse) will report to Fitzgerald. source
• Fitzgerald currently serves as executive vice president and group president, Cardiovascular, Boston Scientific. source